Indication
Recurrent High Grade Uterine Cancer
1 clinical trial
1 product
1 drug
Clinical trial
Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine CancerStatus: Not yet recruiting, Estimated PCD: 2029-01-03
Drug
TiragolumabProduct
Batiraxcept